N Saijo
About
In The Last Decade
N Saijo
25 papers receiving 574 citations
Peers
Comparison fields: 5 of 81
- Molecular Biology 302
- Oncology 277
- Pulmonary and Respiratory Medicine 121
- Surgery 70
- Epidemiology 66
Countries citing papers authored by N Saijo
This map shows the geographic impact of N Saijo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Saijo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Saijo more than expected).
Fields of papers citing papers by N Saijo
This network shows the impact of papers produced by N Saijo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Saijo. The network helps show where N Saijo may publish in the future.
Co-authorship network of co-authors of N Saijo
This figure shows the co-authorship network connecting the top 25 collaborators of N Saijo. A scholar is included among the top collaborators of N Saijo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Saijo. N Saijo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 1 | |
| 3 | In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. | 57 |
| 4 | Specific expression of HSP47 in human tumor cell lines in vitro. | 38 |
| 5 | Specific regulation of HSPs in human tumor cell lines by PSK. | 8 |
| 6 | Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. | 49 |
| 7 | Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. | 148 |
| 8 | 82 | |
| 9 | [Cell cycle regulation by anticancer agent]. | 2 |
| 10 | In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. | 21 |
| 11 | [Effect of cisplatin on cell cycle regulators]. | 2 |
| 12 | [Anticancer agents and apoptosis]. | 1 |
| 13 | Chemotherapy for cervix cancer. | 40 |
| 14 | Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. | 63 |
| 15 | Can cytotoxic activity of anthracyclines be related to DNA damage? | 9 |
| 16 | 15 | |
| 17 | Synergistic effect of recombinant interleukin-2 on the inhibition of growth of adenocarcinoma 755 by mitomycin. | 3 |
| 18 | [Role of asialo GM 1 positive cells in the control of metastatic spread of tumor cells in mice]. | 1 |
| 19 | A spectrophotometric quantitation of cytotoxic action of antiserum and complement by trypan blue. | 12 |
| 20 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.